{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Protocol amendment summary of changes table', 'Section No. and name', 'Description of change', 'Brief rationale', 'Section 4 - Introduction', 'Added the following adverse events of special interest', 'Update of safety information based', '(AESIs) to \"Alemtuzumab Post-Marketing Updates in', 'on post marketing experience in', \"Adult':\", 'adults with multiple sclerosis (MS).', '-', 'Autoimmune encephalitis', '-', 'Thrombotic thrombocytopenic purpura', 'Section 10.4.1.3 - Adverse', 'Added the following AESIs:', 'Update of the safety information', 'events of special interest', '-', 'Autoimmune encephalitis', 'based on post marketing experience', 'in adults with MS.', '-', 'Thrombotic thrombocytopenic purpura', 'Section 10.4.6 - Table 9', '-', 'Added the following AESIs:', 'Update of the safety information', 'Summary of adverse event', '-', 'Autoimmune encephalitis', 'based on post marketing experience', 'reporting instructions', 'in adults with MS.', '-', 'Thrombotic thrombocytopenic purpura', 'Property of the Sanofi Group - strictly confidential', 'Page 3', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'NAMES AND ADDRESSES OF', 'COORDINATING', 'Name:', 'INVESTIGATOR', 'Address:', 'Tel:', 'Fax:', 'E-mail:', \"MONITORING TEAM'S\", 'Name:', 'REPRESENTATIVE', 'Address:', 'Tel:', 'Fax:', 'E-mail:', 'SPONSOR', 'Company:', 'Sanofi Genzyme', 'Address:', '50 Binney St', 'Cambridge, MA 02142 USA', 'OTHER EMERGENCY', 'TELEPHONE NUMBERS', 'Property of the Sanofi Group - strictly confidential', 'Page 4', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'CLINICAL TRIAL SUMMARY', 'COMPOUND: GZ402673 (Alemtuzumab)', 'STUDY No.: EFC13429', 'TITLE', 'A multi-center, open-label, single-arm, before and after switch study to', 'evaluate the efficacy, safety and tolerability of alemtuzumab in', 'paediatric patients with relapsing remitting multiple sclerosis (RRMS)', 'with disease activity on prior disease modifying therapy (DMT)', 'INVESTIGATORITRIAL LOCATION', 'Multinational', 'PHASE OF DEVELOPMENT', '3', 'STUDY OBJECTIVES', 'Primary objective:', 'To evaluate the efficacy, safety and tolerability of', 'alemtuzumab intravenously (IV) in paediatric patients from', '10 to <18 years of age with RRMS who have disease activity', 'on prior DMT.', 'Secondary objective:', 'To assess the pharmacokinetics (PK), pharmacodynamics', '(PD), antidrug antibody (ADA) formation, and potential effects', 'of alemtuzumab on other multiple sclerosis (MS) disease', 'characteristics such as cognition and quality of life (QoL).', 'STUDY DESIGN', 'Open-label, rater-blinded, single-arm, before and after switch study of', 'efficacy, safety and tolerability of alemtuzumab in paediatric patients', 'from 10 to <18 years of age with RRMS with disease activity on prior', 'DMT.', 'The study will consist of:', 'Screening period (0-28 days prior to M-4) - This phase', 'consists of the screening assessments for study eligibility of', 'patients on current DMT.', 'Prior DMT phase (approximately 4 months) - This phase', 'consists of the efficacy measurements on current DMT, which', 'will be used as comparator group in the study. Subjects will', 'continue the use of their current DMT (limited to beta', 'interferon therapy [IFNB] or glatiramer acetate [GA]) during', 'this period until 7 days prior to administration of first dose of', 'alemtuzumab at MO.', 'Alemtuzumab treatment phase (approximately 2 years) - This', 'phase starts with administration of first dose of alemtuzumab', 'at M0, after discontinuation of current DMT, and ends at M24.', 'The second dose of alemtuzumab will be administered at', 'M12. The MRI based primary efficacy endpoint will be', 'assessed over a 4 month period during the treatment phase', 'compared to an equal period during the prior DMT phase.', 'Note: EOTP refers to the end of the Alemtuzumab Treatment', 'Phase.', 'Safety monitoring phase (approximately 3 years) - Additional', 'safety follow-up and monitoring for all patients treated with', 'alemtuzumab will be conducted during this phase to yield a', 'total of 5 years of follow-up since first alemtuzumab', 'Property of the Sanofi Group - strictly confidential', 'Page 5', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}